Medical News
Latest News on Primary Aldosteronism
- Effects of different treatment modalities on cardiovascular disease in ARR-positive hypertensive patients April 17, 2024Hypertension Research - Effects of different treatment modalities on cardiovascular disease in ARR-positive hypertensive patientsNature
- Re: The impact of superselective adrenal artery embolization on renal function in patients with primary aldosteronism: a prospective cohort study April 9, 2024Hypertension Research - Re: The impact of superselective adrenal artery embolization on renal function in patients with primary aldosteronism: a prospective cohort studyNature
- Where and how are we going? Simplifying the definitive diagnosis of primary aldosteronism April 8, 2024Hypertension Research - Where and how are we going? Simplifying the definitive diagnosis of primary aldosteronismNature
- Renal Stones and Primary Aldosteronism April 3, 2024There are few data describing the association between primary aldosteronism (PA) and nephrolithiasis. The reason for recurrent calcium nephrolithiasis may be related to the ...Docwire News
- The effect of different treatment strategies on glycolipid metabolism disorders and cardiovascular events in primary aldosteronism April 2, 2024Hypertension Research - The effect of different treatment strategies on glycolipid metabolism disorders and cardiovascular events in primary aldosteronismNature
- Prediction of endogenous mineralocorticoid receptor activity by depressor effects of mineralocorticoid receptor antagonists in patients with primary aldosteronism March 28, 2024Hypertension Research - Prediction of endogenous mineralocorticoid receptor activity by depressor effects of mineralocorticoid receptor antagonists in patients with primary aldosteronismNature
- Frontiers | Comparison of saline infusion test and captopril challenge test in the diagnosis of Chinese with primary aldosteronism in different age groups March 22, 2024BackgroundTo explore the diagnostic accuracy and the optimal cutoff value between the saline infusion test (SIT) and captopril challenge test (CCT) [includin...frontiersin.org
PA Foundation in the News
- Primary Aldosteronism AllianceIn September 2022, the PA Foundation announced the creation of a multistakeholder alliance to drive diagnosis and treatment of primary aldosteronism.
- Dietary Sodium Global Call to ActionThe PA Foundation is one of the co-authors of the World Hypertension League’s call to action published in May 2022 by the Journal of Human Hypertension.
- BMJ Practice Series: Easily Missed?The PA Foundation co-authored the article of the BMJ Practice Series on primary aldosteronism. The open access article was published in April 2022.
- Doctors Overlook a Curable Cause of High BPMIT’s magazine, Undark, featured the PA Foundation in an article of its February 2022 edition dedicated to primary aldosteronism.
Notable Publications of the Year
Primary Aldosteronism in the EROver 40% of patients presenting to the ER of an Australian tertiary health network met the criteria for PA testing. Only 2% were screened.
BPA and Primary Aldosteronism ScreeningImplementation of an EHR best-practice advisory yielded a screening rate of 14%. Most orders were placed by internists (40%) and primary care physicians (28%).
AVS and Asymmetrical Bilateral PAMultifocal, asymmetrical bilateral PA cannot be excluded by robust AVS lateralization. The study’s independent predictors of postoperative residual PA included Black race, AVS lateralization only at baseline, and CT-AVS disagreement.
68Ga-Pentixafor PET/CT and Subtyping of PAIn a study of 123 patients with adrenal micronodules, the sensitivity, specificity, and accuracy of 68Ga-pentixafor PET/CT in subtyping primary aldosteronism were 90.2%, 86.3%, and 89.4%, respectively. The accuracy of AVS examination was lower than that of PET/CT.
Latest News on Hypertension
- Common Blood Pressure Drug Increases Lifespan And Slows Aging in Animals April 26, 2024A potentially huge discovery.ScienceAlert
- FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) April 26, 2024WINREVAIR is a breakthrough biologic for this rare, progressive disease WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has […]Merck.com
- Idorsia’s Novel Hypertension Pill Among Eight New Drugs To Win EMA Nod April 26, 2024The European Medicines Agency believes Idorsia’s Jeraygo should be approved for use in the EU at two different doses rather than just the one approved by the US Food and Drug Administration last month.Pink Sheet
- OMRON Donates Some 3,200 Units of Blood Pressure Monitors to Global Blood Pressure Screening Campaign on World Hypertension Day April 26, 2024OMRON Donates Some 3,200 Units of Blood Pressure Monitors to Global Blood Pressure Screening Campaign on World Hypertension DayHindustan Times
- JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension April 26, 2024Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.A CHMP positive opinion is […]Idorsia Pharmaceuticals Ltd
- Immune cells play a bigger role in high blood pressure than previously thought, opening doors for new treatments April 26, 2024A review in Nature Reviews Nephrology presents the association between immune cells and the development of hypertension, suggesting potential new therapeutic targets to mitigate the disease by managing inflammation.News-Medical